Studies will be undertaken to gain further insight into the biological and biochemical effects of the human interferons so as to further elucidate their mechanism(s) of action and ascertain how they can best be employed therapeutically. One of the proposed aims is to produce polyclonal and monoclonal antibodies directed against the proteins induced in interferon-treated cells. These antibodies will be used to examine the interferon-treated cells, to ascertain whether the induced proteins synthesized in response to the different human interferons are structurally and antigenically related and to determine whether these interferon-induced proteins play a role in the action of the interferon-induced enzyme activities. Methodologies will also be developed and employed which will allow for a determination of the responsiveness of freshly removed tumor tissues to the effects of the different human interferons. This methodology will use as a measure of responsiveness to the interferons the ability of the tumor cells to synthesize the interferon-induced proteins. This measurement will be accomplished by using the antibodies directed against the interferon-induced proteins to either immunoprecipitate radioactively-labeled interferon-induced proteins from the interferon-treated tumor cells or to stain the interferon-treated tumor cells for the presence of the interferon-induced proteins. A determination of the rsponsiveness to the interferons could be made rapidly (in 24 hr) and would allow clinicians to select patients for interferon therapy that are capable of responding to the interferon. The interferons have been found to differ in their abilities to inhibit the replication of different viruses. This comparison will be extended to include other clinically relevant viruses (e.g., adenovirus and herpes simplex virus) to determine which of the interferons is best capable of inhibiting the replication of these viruses. Purified E. coli-derived Gamma interferon has been shown in this laboratory to have a lower specific activity than leukocyte-derived Gamma interferon. Studies will be undertaken to compare the structural and biological properties of leukocyte and E. coli-derived Gamma interferons and to determine whether this observed difference in specific activity is due to the absence of carbohydrate on the E. coli-derived Gamma interferon.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Virology Study Section (VR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York Blood Center
New York
United States
Zip Code
Anderson, S L; Carton, J M; Lou, J et al. (1999) Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology 256:8-14
Anderson, S L; Carton, J M; Zhang, X et al. (1999) Genomic organization and chromosomal localization of a new member of the murine interferon-induced guanylate-binding protein family. J Interferon Cytokine Res 19:487-94
Lou, J; Anderson, S L; Xing, L et al. (1994) Suppression of mitochondrial mRNA levels and mitochondrial function in cells responding to the anticellular action of interferon. J Interferon Res 14:33-40
Bandyopadhyay, S K; Kumar, R; Rubin, B Y et al. (1992) Interferon-inducible gene expression in HL-60 cells: effects of the state of differentiation. Cell Growth Differ 3:369-75
Squires, K E; Schreiber, R D; McElrath, M J et al. (1989) Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 143:4244-9
Murray, H W; Szuro-Sudol, A; Wellner, D et al. (1989) Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun 57:845-9
Rubin, B Y; Anderson, S L; Lunn, R M et al. (1989) Induction of proteins in interferon-alpha- and interferon-gamma-treated polymorphonuclear leukocytes. J Leukoc Biol 45:396-400
Rubin, B Y; Anderson, S L; Lunn, R M et al. (1989) Fragmentation of cellular DNA is a nonspecific indicator of responsiveness to tumor necrosis factor. J Biol Response Mod 8:553-9
Rubin, B Y; Anderson, S L; Lunn, R M et al. (1988) Tumor necrosis factor and IFN induce a common set of proteins. J Immunol 141:1180-4
Murray, H W; Scavuzzo, D A; Kelly, C D et al. (1988) T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome. Arch Intern Med 148:1613-6

Showing the most recent 10 out of 30 publications